Evidence map›Paper›PMID 37509222›Full record

ArticleCancers2023

Targeting Oncogenic Wnt/β-Catenin Signaling in Adrenocortical Carcinoma Disrupts ECM Expression and Impairs Tumor Growth.

Morgan K Penny, Antonio M Lerario, Kaitlin J Basham, Sahiti Chukkapalli, Dipika R Mohan, Chris LaPensee, Kimber Converso-Baran, Mark J Hoenerhoff, Laura Suárez-Fernández, Carmen González Del Rey and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Morgan K PennyDoctoral Program in Cancer Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.ORCID 0000-0002-7449-1098
Antonio M LerarioDepartment of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-8336-6432
Kaitlin J BashamDepartment of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0001-6607-8167
Sahiti ChukkapalliMott Solid Tumor Oncology Program, C.S. Mott Children's and Women's Hospital, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Dipika R MohanDoctoral Program in Cancer Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Chris LaPenseeDepartment of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
Kimber Converso-BaranUMH Frankel Cardiovascular Center Physiology and Phenotyping Core, Ann Arbor, MI 48109, USA.
Mark J HoenerhoffIn Vivo Animal Core, Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Laura Suárez-FernándezDepartment Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias, 33011 Oviedo, Spain.
Carmen González Del ReyDepartment of Pathology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, 33011 Oviedo, Spain.
Thomas J GiordanoDepartment of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
Ruolan HanIterion Therapeutics, Inc., Houston, TX 77021, USA.
Erika A NewmanMott Solid Tumor Oncology Program, C.S. Mott Children's and Women's Hospital, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Gary D HammerDepartment of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0001-6843-3628
University of Michigan · USInstituto de Investigación Sanitaria del Principado de Asturias · ESMichigan Medicine · US

Funding

Mechanisms of Adrenal DifferentiationR01DK062027 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GARY D. HAMMER · 2004 to 2026
$8.0M
Training Program in Tumor MicroenvironmentT32CA009676 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro, Analisa Virginia DiFeo · 1992 to 2026
$7.3M
NCI NIH HHS T32 CA009676NIDDK NIH HHS R01 DK062027NIH HHS R01 DK062027NIH HHS T32 CA009676
6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is a rare but highly aggressive cancer with limited treatment options and poor survival for patients with advanced disease. An improved understanding of the transcriptional programs engaged in ACC will help direct rational, targeted therapies. Whereas activating mutations in Wnt/β-catenin signaling are frequently observed, the β-catenin-dependent transcriptional targets that promote tumor progression are poorly understood. To address this question, we analyzed ACC transcriptome data and identified a novel Wnt/β-catenin-associated signature in ACC enriched for the extracellular matrix (ECM) and predictive of poor survival. This suggested an oncogenic role for Wnt/β-catenin in regulating the ACC microenvironment. We further investigated the minor fibrillar collagen, collagen XI alpha 1 (COL11A1), and found that

Indexed as

adrenaladrenocortical carcinomaCOL11A1collagenextracellular matrixtargeted therapyWntWnt/β-cateninxenograftβ-catenin

Identifiers

PMID37509222
PMCPMC10377252
OpenAlexW4383877444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.